Aliases & Classifications for Dementia

MalaCards integrated aliases for Dementia:

Name: Dementia 12 72 50 28 51 40 3 14 69
Presenile Dementia 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1307
ICD9CM 34 290.8

Summaries for Dementia

NINDS : 50 Dementia is the loss of cognitive functioning—the ability to think, remember, problem solve or reason—to such an extent that it interferes with a person’s daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person’s functioning, to the most severe stage, when the person must depend completely on others for basic activities of daily living. Functions affected include memory, language skills, visual perception, problem solving, self-management, and the ability to focus and pay attention. Some people with dementia cannot control their emotions, and their personalities may change. Signs and symptoms of dementia result when once-healthy neurons (nerve cells) in the brain stop working, lose connections with other brain cells, and die. While everyone loses some neurons as they age, people with dementia experience far greater loss. Unlike dementia, age-related memory loss isn’t disabling. While dementia is more common with advanced age (as many as half of all people age 85 or older may have some form of dementia), it is not normal part of aging. Many people live into their 90s and beyond without any signs of dementia. The causes of dementia can vary. Many people with dementia have both Alzheimer’s disease and one or more closely related disorders that share brain scanning or clinical (and sometimes both) features with Alzheimer’s disease. When a person is affected by more than one dementia disorder, the dementia can be referred to as a mixed dementia. Some people may have mixed dementia caused by Alzheimer’s-related neurodegenerative processes, vascular disease-related processes, or another neurodegenerative condition. Many other conditions such as Creutzfeldt-Jakob disease, Huntington’s Disease, and chronic traumatic encephalopathy can cause dementia or dementia-like symptoms. Risk factors for dementia include advancing age, stroke, high blood pressure, poorly controlled diabetes, and a thickening of blood vessel walls (atherosclerosis). Other dementias include frontotemporal disorders, vascular dementia, and Lewy body dementia.

MalaCards based summary : Dementia, also known as presenile dementia, is related to semantic dementia and frontotemporal lobar degeneration with tdp43 inclusions, grn-related, and has symptoms including sleeplessness, equilibration disorder and vertigo/dizziness. An important gene associated with Dementia is PSEN1 (Presenilin 1), and among its related pathways/superpathways are Presenilin-Mediated Signaling and Neuroscience. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and cellular

MedlinePlus : 40 Dementia is the name for a group of symptoms caused by disorders that affect the brain. It is not a specific disease. People with dementia may not be able to think well enough to do normal activities, such as getting dressed or eating. They may lose their ability to solve problems or control their emotions. Their personalities may change. They may become agitated or see things that are not there. Memory loss is a common symptom of dementia. However, memory loss by itself does not mean you have dementia. People with dementia have serious problems with two or more brain functions, such as memory and language. Although dementia is common in very elderly people, it is not part of normal aging. Many different diseases can cause dementia, including Alzheimer's disease and stroke. Drugs are available to treat some of these diseases. While these drugs cannot cure dementia or repair brain damage, they may improve symptoms or slow down the disease. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 The role of public health in enhancing the physical health of older adults is well-known. Public health’s role in maintaining cognitive health, a vital part of healthy aging and quality of life, is emerging. The need for a clearly delineated public health role comes at a critical time given the dramatic aging of the U.S. population, scientific advancements in knowledge about risk behaviors (e.g., lack of physical activity, uncontrolled high blood pressure) related to cognitive decline, and the growing awareness of the significant health, social, and economic burdens associated with cognitive decline. The Healthy Brain Initiative is a multifaceted approach to cognitive health with several components, including:

Disease Ontology : 12 A cognitive disorder resulting from a loss of brain function affecting memory, thinking, language, judgement and behavior.

Wikipedia : 72 Dementia is a broad category of brain diseases that cause a long-term and often gradual decrease in the... more...

Related Diseases for Dementia

Diseases related to Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 602)
# Related Disease Score Top Affiliating Genes
1 semantic dementia 34.3 APOE GRN MAPT
2 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 33.8 GRN MAPT
3 vascular dementia 33.8 APOE APP MAPT NOTCH3 PRNP PSEN1
4 dementia, lewy body 33.7 APOE APP GRN MAPT PRNP PSEN1
5 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 33.5 C9orf72 CHCHD10 CHMP2B FUS GRN PSEN1
6 cerebral amyloid angiopathy, itm2b-related, 1 33.2 APP ITM2B SERPINI1
7 behavioral variant of frontotemporal dementia 33.1 C9orf72 CHMP2B GRN MAPT PSEN1 SQSTM1
8 binswanger's disease 33.1 APOE APP MAPT NOTCH3
9 pick disease of brain 33.1 APOE APP FUS GRN MAPT PSEN1
10 prion disease 33.0 APP MAPT PRNP
11 creutzfeldt-jakob disease 33.0 APOE MAPT PRNP
12 leukoencephalopathy, hereditary diffuse, with spheroids 32.9 APP MAPT PRNP SNCA
13 alzheimer disease 32.8 APOE APP GRN ITM2B MAPT PRNP
14 frontotemporal dementia 32.7 APOE APP C9orf72 CHCHD10 CHMP2B FUS
15 posterior cortical atrophy 32.4 APOE MAPT
16 genetic prion diseases 32.3 APOE PRNP
17 multiple system atrophy 1 32.2 MAPT SNCA SNCB SQSTM1
18 supranuclear palsy, progressive, 1 32.1 APOE APP C9orf72 GRN MAPT PSEN1
19 cerebral amyloid angiopathy, cst3-related 32.1 APOE APP ITM2B MAPT PRNP PSEN1
20 amyotrophic lateral sclerosis type 14 32.1 FUS UBQLN2 VCP
21 parkinson disease, late-onset 32.0 APOE APP MAPT SNCA SNCB SQSTM1
22 amyotrophic lateral sclerosis 21 31.9 C9orf72 FUS VCP
23 alzheimer disease 2 31.9 APOE APP MAPT PSEN1 PSEN2
24 perry syndrome 31.9 C9orf72 GRN SNCA
25 amyotrophic lateral sclerosis 1 31.8 APP C9orf72 CHCHD10 CHMP2B FUS GRN
26 aphasia 31.7 APOE APP C9orf72 CHMP2B GRN MAPT
27 kluver-bucy syndrome 31.7 APP MAPT PSEN1
28 alzheimer disease 4 31.6 APOE PSEN1 PSEN2
29 familial idiopathic basal ganglia calcification 31.4 APOE APP MAPT PSEN1 PSEN2
30 lateral sclerosis 30.9 C9orf72 CHCHD10 CHMP2B FUS SQSTM1 UBQLN2
31 apraxia 30.9 C9orf72 GRN MAPT
32 motor neuron disease 30.8 C9orf72 CHCHD10 FUS GRN MAPT SQSTM1
33 tremor 30.8 FUS MAPT SNCA
34 amyloidosis 30.4 APOE APP PSEN1 SNCA
35 alexia 30.4 APOE PSEN1
36 synucleinopathy 30.4 APP CHMP2B MAPT SNCA SNCB
37 prosopagnosia 30.3 GRN PSEN1
38 agraphia 30.2 GRN MAPT PRNP PSEN1
39 gait apraxia 30.1 APOE APP GRN PSEN1
40 progressive non-fluent aphasia 30.1 C9orf72 CHMP2B GRN MAPT PSEN1 VCP
41 senile plaque formation 30.1 APOE APP
42 speech and communication disorders 30.0 APOE C9orf72 GRN MAPT PSEN1
43 cerebral hemorrhage 30.0 APP PRNP
44 akinetic mutism 29.9 MAPT PRNP
45 visual agnosia 29.9 GRN PSEN1 PSEN2
46 ideomotor apraxia 29.8 FUS GRN MAPT PSEN1
47 toxic encephalopathy 29.8 APP PRNP SNCA
48 nominal aphasia 29.4 C9orf72 CHMP2B FUS GRN MAPT PSEN1
49 mutism 29.3 CHMP2B GRN
50 early-onset familial alzheimer disease 29.2 APP ITM2B MAPT PSEN1 PSEN2 SERPINI1

Graphical network of the top 20 diseases related to Dementia:



Diseases related to Dementia

Symptoms & Phenotypes for Dementia

UMLS symptoms related to Dementia:


sleeplessness, equilibration disorder, vertigo/dizziness, chronic pain, tremor, syncope, seizures, sciatica, pain, headache, back pain, angina pectoris

MGI Mouse Phenotypes related to Dementia:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.4 SERPINI1 SNCA SQSTM1 TYROBP VCP APOE
2 cellular MP:0005384 10.32 VCP SQSTM1 TYROBP APOE APP C9orf72
3 growth/size/body region MP:0005378 10.31 APOE APP C9orf72 MAPT NOTCH3 PRNP
4 hematopoietic system MP:0005397 10.26 VCP APOE APP C9orf72 GRN MAPT
5 immune system MP:0005387 10.25 APOE APP C9orf72 GRN MAPT NOTCH3
6 homeostasis/metabolism MP:0005376 10.23 SNCB SQSTM1 TYROBP APOE APP GRN
7 mortality/aging MP:0010768 10.18 APOE APP C9orf72 GRN MAPT NOTCH3
8 nervous system MP:0003631 10.16 APOE APP C9orf72 CHMP2B GRN ITM2B
9 integument MP:0010771 10.1 APOE APP MAPT NOTCH3 PRNP PSEN1
10 muscle MP:0005369 9.87 APOE APP MAPT NOTCH3 PRNP PSEN1
11 no phenotypic analysis MP:0003012 9.81 C9orf72 GRN ITM2B MAPT PRNP SNCA
12 normal MP:0002873 9.56 APP MAPT NOTCH3 PRNP PSEN1 PSEN2
13 skeleton MP:0005390 9.28 APOE NOTCH3 PRNP PSEN1 SNCA SNCB

Drugs & Therapeutics for Dementia

Drugs for Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 837)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054
3
Levodopa Approved Phase 4,Phase 2,Phase 3,Phase 1 59-92-7 6047
4
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
5
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 20748-11-2, 113-45-1 4158
6
Galantamine Approved Phase 4,Phase 3,Phase 2,Phase 1 357-70-0 9651
7
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2 106266-06-2 5073
8
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120014-06-4 3152
9
Huperzine A Approved, Investigational Phase 4,Phase 2,Phase 3 102518-79-6
10
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
11
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 4091 14219
12
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 123441-03-2 77991
13
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757
14
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3 71-58-9
15
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3 57-83-0 5994
16
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 2216-51-5 16666
17
Nimodipine Approved, Investigational Phase 4,Phase 1 66085-59-4 4497
18
Rasagiline Approved Phase 4,Phase 2 136236-51-6 3052776
19
Cilostazol Approved, Investigational Phase 4,Phase 2 73963-72-1 2754
20
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 93-14-1 3516
21
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2 13422-51-0 5460373 44475014 11953898
22
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2 112111-43-0
23
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2 68693-11-8 4236
24
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
25
Dextromethorphan Approved Phase 4,Phase 3,Phase 1,Phase 2 125-71-3 5362449 5360696
26
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Early Phase 1 15687-27-1 3672
27
Nicotine Approved Phase 4,Phase 2,Phase 1 54-11-5 89594 942
28
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1 2078-54-8 4943
29
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
30
Isoflurane Approved, Vet_approved Phase 4,Phase 1 26675-46-7 3763
31
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 99-66-1 3121
32
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
33
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
34
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
35
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 61869-08-7 43815
36
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1 79617-96-2 68617
37
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 52485-79-7 644073 40400
38
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
39
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
40
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
41
Nicergoline Approved, Investigational Phase 4,Phase 3 27848-84-6 34040
42 Piracetam Approved, Investigational Phase 4,Phase 3,Phase 2 7491-74-9
43
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
44
Quinidine Approved, Investigational Phase 4,Phase 3,Phase 2 56-54-2 441074
45
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
46
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 1 129722-12-9 60795
47
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3 154598-52-4 64139
48
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 134678-17-4 60825
49
Nevirapine Approved Phase 4,Phase 2,Phase 3 129618-40-2 4463
50
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1 30516-87-1 35370

Interventional clinical trials:

(show top 50) (show all 2956)

# Name Status NCT ID Phase Drugs
1 Memantine for Agitation in Dementia Unknown status NCT00371059 Phase 4 Memantine;Placebo
2 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment Unknown status NCT00306124 Phase 4 Levodopa
3 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
4 Improving Function, Quality of Life, Glycemia in Diabetics With Dementia Unknown status NCT00792662 Phase 4 Methylphenidate;Placebo
5 The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD) Unknown status NCT00626613 Phase 4 Risperdal,reminyl
6 Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI Unknown status NCT01329601 Phase 4
7 CALM-AD Unknown status NCT00142324 Phase 4 Donepezil
8 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
9 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
10 Donepezil and Memantine in Moderate to Severe Alzheimer's Disease Unknown status NCT00866060 Phase 4 Memantine;Donepezil;Placebo donepezil;Placebo memantine
11 Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study Unknown status NCT02409238 Phase 4 Metformin
12 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4 Rivastigmine
13 Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study Unknown status NCT02190019 Phase 4
14 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
15 Cognitive Decline in Non-demented PD Unknown status NCT01340885 Phase 4 Strattera;Exelon
16 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
17 Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®) Unknown status NCT00523666 Phase 4 Galantamine (Reminyl®);Placebo/Galantamine (Reminyl®)
18 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
19 Atrial Fibrillation and the Risk for Neurological Complications Unknown status NCT00357227 Phase 4
20 Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease Unknown status NCT00354133 Phase 4
21 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
22 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4 AZILECT®;Placebo
23 Study of Memantine to Treat Huntington's Disease Unknown status NCT00652457 Phase 4 Memantine
24 Cilostazol Augmentation Study in Dementia Completed NCT01409564 Phase 4 Cilostazol;Placebo
25 Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
26 Corticolimbic Degeneration and Treatment of Dementia Completed NCT00768261 Phase 4 Memantine (Namenda®);Memantine (Namenda®);Donepezil (Aricept®)
27 A Study on Behavioral and Psychological Symptoms of Dementia Completed NCT00641459 Phase 4
28 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed NCT00385684 Phase 4 hydrocodone/APAP w placebo PRN;hydrocodone/APAP;placebo with hydrocodone/APAP PRN
29 Dementia Antipsychotics And Antidepressants Discontinuation Study Completed NCT00594269 Phase 4 Risperidone;Escitalopram;Citalopram;Sertraline;Paroxetine
30 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
31 Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia Completed NCT01585272 Phase 4 ENA713
32 Can Oral Vitamin B12 and Folate Supplementation Preserve Cognitive Function of Patients With Early Dementia? Completed NCT00164970 Phase 4
33 Effect of Melatonin on Sleep Quality in Patients Dementia Completed NCT03066518 Phase 4 Melatonin 5 mg
34 The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life Completed NCT00814658 Phase 4 Galantamine;Nimodipine;Placebo
35 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
36 Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4 Memantine;Placebo
37 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4 Armodafinil
38 Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and Mini Mental State Examination (MMSE)Range 5 - 18 Completed NCT02553928 Phase 4 Memantine (once daily);Memantine (twice daily)
39 Study on the Efficacy of Speed-Feedback Therapy for Elderly People With Dementia Completed NCT00450047 Phase 4
40 Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study Completed NCT00495820 Phase 4 Methylphenidate
41 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions Completed NCT00847860 Phase 4 Cilostazol;Aspirin
42 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
43 Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD Completed NCT00433121 Phase 4 Risperidone;Olanzapine;Haloperidole;Quetiapin;Escitalopram;Citalopram;Sertralin
44 Prospective Research in Memory Clinics (PRIME) Completed NCT00297271 Phase 4
45 A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
46 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4 Quetiapine
47 A Comparison of Two Standard Therapies in the Management of Dementia With Agitation Completed NCT00208819 Phase 4 risperidone;quetiapine;olanzapine;divalproex
48 Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease Completed NCT00283725 Phase 4
49 A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints Completed NCT00276510 Phase 4 EGb 761® (Tanakan®)
50 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 Completed NCT00948766 Phase 4 Rivastigmine 4.6 mg/24 h (5 cm^2);Rivastigmine 9.5 mg/24 h (10 cm^2);Rivastigmine 13.3 mg/24 h (15 cm^2);Placebo

Search NIH Clinical Center for Dementia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Dementia

Genetic tests related to Dementia:

# Genetic test Affiliating Genes
1 Dementia 28

Anatomical Context for Dementia

MalaCards organs/tissues related to Dementia:

38
Brain, Testes, Heart, Cortex, Bone, Eye, Temporal Lobe

Publications for Dementia

Articles related to Dementia:

(show top 50) (show all 5157)
# Title Authors Year
1
Posterior Associative and Cingulate Cortex Involvement of Brain Single-Photon Emission Computed Tomography (SPECT) Imaging in Semantic Dementia with Probable Alzheimer Disease Pathology: A Case Report. ( 29429985 )
2018
2
Mitochondrial factor and cell cytokines associate with TCM syndrome scale in vascular dementia patients. ( 29375680 )
2018
3
Psychiatric symptoms in preclinical behavioural-variant frontotemporal dementia in<i>MAPT</i>mutation carriers. ( 29353234 )
2018
4
Reply: Cerebrospinal Fluid, Hyposmia and Dementia in Alzheimer Disease: Insights from Dynamic PET and a Hypothesis. ( 29439014 )
2018
5
Predicting outcome of Morris water maze test in vascular dementia mouse model with deep learning. ( 29415035 )
2018
6
Strategic value-directed learning and memory in Alzheimer's disease and behavioural-variant frontotemporal dementia. ( 29431279 )
2018
7
<i>ABCA7</i> and risk of dementia and vascular disease in the Danish population. ( 29376091 )
2018
8
Beyond the face: how context modulates emotion processing in frontotemporal dementia subtypes. ( 29394332 )
2018
9
Meaning of psychiatric symptoms in frontotemporal dementia. ( 29439161 )
2018
10
Acupuncture Prevents the Impairment of Hippocampal LTP Through I^1-AR in Vascular Dementia Rats. ( 29435917 )
2018
11
Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis. ( 29378861 )
2018
12
Plasma tau is increased in frontotemporal dementia. ( 29440230 )
2018
13
Vitamin D status and risk of dementia and Alzheimer's disease: A meta-analysis of dose-response. ( 29447107 )
2018
14
Cathepsin D Polymorphism C224T in Childhood-Onset Neurodegenerative Disorders: No Impact for Childhood Dementia. ( 29441216 )
2018
15
A Case of Rapidly Progressing Frontotemporal Dementia. ( 29403137 )
2018
16
Slowly progressive behavioral frontotemporal dementia with C9orf72 mutation. Case report and review of the literature. ( 29355451 )
2018
17
Molecular Pharmacology of Rosmarinic and Salvianolic Acids: Potential Seeds for Alzheimer's and Vascular Dementia Drugs. ( 29401682 )
2018
18
Albuminuria Increases the Risks for Both Alzheimer Disease and Vascular Dementia in Community-Dwelling Japanese Elderly: The Hisayama Study. ( 29353232 )
2018
19
Clinical prevalence of Lewy body dementia. ( 29448953 )
2018
20
Mutation Screening of the CHCHD2 Gene for Alzheimer's Disease and Frontotemporal Dementia in Chinese Mainland Population. ( 29376860 )
2018
21
Autoimmunity and Frontotemporal Dementia. ( 29357796 )
2018
22
Anosognosia predicts default mode network hypometabolism and clinical progression to dementia. ( 29444971 )
2018
23
Animal-Assisted Intervention and Dementia: A Systematic Review. ( 29441797 )
2018
24
Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnestic MCI and AD dementia. ( 29446123 )
2018
25
Ligustrazine suppresses neuron apoptosis via the Bax/Bcl-2 and caspase-3 pathway in PC12 cells and in rats with vascular dementia. ( 29247598 )
2018
26
Validity and Reliability of the Frontotemporal Dementia Rating Scale (FTD-FRS) for the Progression and Staging of Dementia in Brazilian Patients. ( 29438114 )
2018
27
Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer's disease. ( 29441654 )
2018
28
Polypharmacy in people with dementia: Associations with adverse health outcomes. ( 29452289 )
2018
29
Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. ( 29438037 )
2018
30
Diagnosing dementia in lower educated older persons: validation of a Brazilian Portuguese version of the Rowland Universal Dementia Assessment Scale (RUDAS). ( 29451587 )
2018
31
Dementia clinical trial implications of mild behavioral impairment. ( 29448970 )
2018
32
Nanotherapy for Alzheimer's disease and vascular dementia: Targeting senile endothelium. ( 29274774 )
2018
33
Friendship, curiosity and the city: Dementia friends and memory walks in Liverpool. ( 29445248 )
2018
34
The Pro-Apoptotic JNK Scaffold POSH/SH3RF1 Mediates CHMP2BIntron5-Associated Toxicity in Animal Models of Frontotemporal Dementia. ( 29432529 )
2018
35
Neurovascular dysfunction in dementia - human cellular models and molecular mechanisms. ( 29444850 )
2018
36
Vascular dementia: clinicopathologic and genetic considerations. ( 29380913 )
2018
37
Dysregulation and Dislocation of SFPQ Disturbed DNA Organization in Alzheimer's Disease and Frontotemporal Dementia. ( 29376859 )
2018
38
Reading and visual word recognition ability in semantic dementia is not predicted by semantic performance. ( 29432768 )
2018
39
Cognitive impairment in Parkinson's disease, Alzheimer's dementia, and vascular dementia: the role of the clock-drawing test. ( 29417704 )
2018
40
Chinese Herbal Medicine for Vascular Dementia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. ( 29439346 )
2018
41
Lacosamide in the Management of Behavioral Symptoms in Frontotemporal Dementia: A 2-Case Report. ( 29389672 )
2018
42
Connectivity-based characterisation of subcortical grey matter pathology in frontotemporal dementia and ALS: a multimodal neuroimaging study. ( 29423814 )
2018
43
Caregiver Reactions to Dementia Symptoms: Effects on Coping Repertoire and Mental Health. ( 29451843 )
2018
44
Combined Socio-Behavioral Evaluation Improves the Differential Diagnosis Between the Behavioral Variant of Frontotemporal Dementia and Alzheimer's Disease: In Search of Neuropsychological Markers. ( 29254091 )
2018
45
Repeated administration of Sailuotong, a fixed combination of Panax ginseng, Ginkgo biloba, and Crocus sativus extracts for vascular dementia, alters CYP450 activities in rats. ( 29425645 )
2018
46
Association of Age-Related Hearing Loss With Cognitive Function, Cognitive Impairment, and Dementia: A Systematic Review and Meta-analysis. ( 29222544 )
2018
47
Effect of Telmisartan on Preventing Learning and Memory Deficits Via Peroxisome Proliferator-Activated Receptor-I^ in Vascular Dementia Spontaneously Hypertensive Rats. ( 29241675 )
2018
48
Facial Emotion Recognition Performance Differentiates Between Behavioral Variant Frontotemporal Dementia and Major Depressive Disorder. ( 29360290 )
2018
49
Special Issue on mild behavioral impairment and non-cognitive prodromes to dementia. ( 29448971 )
2018
50
Neuroprotective effect of berberine chloride on cognitive impairment and hippocampal damage in experimental model of vascular dementia. ( 29372037 )
2018